Immunovant, Inc. (IMVT) intrinsic value & 10-year financials
Immunovant, Inc. (IMVT) has no Graham intrinsic value right now because the formula needs positive earnings.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $26.73
- Market cap
- $4.9B
- Revenue (FY2026)
- —
- ROIC (10-yr avg)
- 1000.6%
- Free cash flow (FY2026)
- -$407.3M
IMVT 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2026 | — | -$505.6M | -$2.77 | -$407.3M | — | -64.8% |
| FY2025 | — | -$413.8M | -$2.73 | -$376.6M | — | 2350.3% |
| FY2024 | — | -$259.3M | -$1.88 | -$214.6M | — | 1641.4% |
| FY2023 | — | -$211.0M | -$1.71 | -$188.4M | — | 1147.6% |
| FY2022 | — | -$156.7M | -$1.43 | -$106.4M | — | 1073.5% |
| FY2021 | — | -$107.4M | -$1.22 | -$83.5M | — | 1661.7% |
| FY2020 | — | -$66.4M | — | -$53.4M | — | 1021.0% |
| FY2019 | — | -$28.6M | — | -$28.6M | — | -825.6% |
| FY2018 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Immunovant, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Immunovant, Inc. returns on capital have been average, hovering around 14.8% ROIC over the decade.
Immunovant, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Immunovant, Inc. is evaluated under Benjamin Graham's defensive framework using SEC EDGAR fundamentals using an 8.5 + 2g earnings multiple and a 5.1% AAA bond-yield baseline.